The European Rare Kidney Disease Reference Network


Journal Watch

Thrombotic microangiopathies

Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.
Author(s): Haskin O, Falush Y, Davidovits M
Source: Pediatr Nephrol 2019 Sep 13;
Publication date: 2019-09-13
New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome.
Author(s): Scobell RR, Kaplan BS, Copelovitch L
Source: Pediatr Nephrol 2019 Sep 13;
Publication date: 2019-09-13
Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase.
Author(s): Sakurai S, Kato H, Yoshida Y, Sugawara Y, Fujisawa M, Yasumoto A, Matsumoto M, Fujimura Y, Yatomi Y, Nangaku M
Source: J Atheroscler Thromb 2019 Sep 4;
Publication date: 2019-09-4
Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.
Author(s): Cavero T, Arjona E, Soto K, Caravaca-Fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-Gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, Praga M
Source: Kidney Int 2019 May 31;
Publication date: 2019-05-31
Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.
Author(s): Zheng L, Zhang D, Cao W, Song W, Zheng XL
Source: Blood 2019 Aug 13;
Publication date: 2019-08-13
+ Show 67 more...

European Reference Networks
ERKNet is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission.
For more information about the ERNs and the EU health strategy, please visit